adamantane has been researched along with Atherogenesis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Gao, C; Kwong, CHT; Lee, SMY; Liu, C; Wang, Q; Wang, R; Wang, Y; Xie, B | 1 |
| Hirano, T; Itoh, F; Katayama, Y; Kohashi, K; Nagashima, M; Nogi, Y; Nohtomi, K; Sato, K; Sinmura, K; Terasaki, M; Tomoyasu, M; Watanabe, T | 1 |
| Liu, YS; Lu, QH; Zhang, J | 1 |
| Aerts, JM; Bietrix, F; Groen, AK; Lombardo, E; Ottenhoff, R; Rensen, PC; van Roomen, CP; Verhoeven, AJ; Vos, M | 1 |
| Barbosa-Sicard, E; Brandes, RP; Fleming, I; Geisslinger, G; Hammock, BD; Liebner, S; Mieth, A; Morisseau, C; Revermann, M; Schermuly, RT; Schloss, M | 1 |
| Bai, SZ; Guo, J; He, W; Kong, FJ; Li, GW; Li, HX; Li, HZ; Tian, Y; Wang, R; Wu, LY; Xi, YH; Xing, WJ; Xu, CQ; Yang, GD | 1 |
| Hirano, T; Miyazaki, A; Mori, Y; Nagashima, M; Nohtomi, K; Terasaki, M; Watanabe, T | 1 |
| Bergonzini, V; Bot, M; Costa, S; Freise, H; Maines, L; Nofer, JR; Poti, F; Robenek, H; Simoni, M; Varga, G | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
2 trial(s) available for adamantane and Atherogenesis
| Article | Year |
|---|---|
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Israel; Matrix Metalloproteinase 9; Metformin; Nitriles; Platelet Function Tests; Prospective Studies; Pyrrolidines; Research Design; Thrombosis; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
8 other study(ies) available for adamantane and Atherogenesis
| Article | Year |
|---|---|
Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis.
Topics: Adamantane; Animals; Atherosclerosis; beta-Cyclodextrins; Cholesterol; Cyclodextrins; Humans; Inflammation; Liposomes; Liver X Receptors; Macrophages; Mice; NF-E2-Related Factor 2; Plaque, Atherosclerotic; Quercetin | 2022 |
Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Topics: Adamantane; Alternative Splicing; Animals; Apolipoproteins E; Atherosclerosis; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Foam Cells; Gene Expression Profiling; Gene Expression Regulation; Gene Order; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Incretins; Macrophages; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Nitriles; Pyrrolidines; Receptors, Glucagon; Vildagliptin | 2013 |
Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases.
Topics: Adamantane; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Cytokines; Enzyme Inhibitors; Epoxide Hydrolases; In Vitro Techniques; Lauric Acids; Mice; Mice, Knockout; NF-kappa B; Plaque, Atherosclerotic; Toll-Like Receptor 4 | 2015 |
Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Apolipoproteins E; Atherosclerosis; Bile; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Feces; Female; Glucosyltransferases; Glycosphingolipids; Hyperlipidemias; Kinetics; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mutation; Receptors, LDL | 2010 |
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Topics: Adamantane; Animals; Apolipoproteins E; Arachidonic Acids; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Femoral Artery; Hyperlipidemias; Hyperplasia; Inflammation Mediators; Lauric Acids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Tunica Intima | 2010 |
Involvement of calcium-sensing receptor in oxLDL-induced MMP-2 production in vascular smooth muscle cells via PI3K/Akt pathway.
Topics: Adamantane; Animals; Anthracenes; Aorta; Atherosclerosis; Cells, Cultured; Chromones; Gadolinium; JNK Mitogen-Activated Protein Kinases; Lipoproteins, LDL; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Morpholines; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing | 2012 |
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Topics: Adamantane; Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dipeptidyl-Peptidase IV Inhibitors; Foam Cells; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Lipoproteins, LDL; Male; Mice; Nitriles; Plaque, Atherosclerotic; Pyrrolidines; Weight Loss | 2012 |
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
Topics: Adamantane; Animals; Atherosclerosis; Cell Adhesion Molecules; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Cytokines; Dendritic Cells; Disease Models, Animal; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Humans; Inflammation Mediators; Mice; Mice, Knockout; Phosphotransferases (Alcohol Group Acceptor); Proprotein Convertases; Pyridines; Receptors, LDL; Serine Endopeptidases; T-Lymphocytes | 2012 |